How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "2388"
  ["article_id"]=>
  string(4) "2388"
  [1]=>
  string(39) "Baxter International Expanding MS Plant"
  ["article_title"]=>
  string(39) "Baxter International Expanding MS Plant"
  [2]=>
  string(153) "&#nl        DEERFIELD, IL—Medical equipment maker Baxter International is expanding its Cleveland, MS, plant, with plans to add 50 to 100 new emplo"
  ["short_description"]=>
  string(153) "&#nl        DEERFIELD, IL—Medical equipment maker Baxter International is expanding its Cleveland, MS, plant, with plans to add 50 to 100 new emplo"
  [3]=>
  string(198) "&#nl        
DEERFIELD, IL—Medical equipment maker Baxter International is expanding its Cleveland, MS, plant, with plans to add 50 to 100 new employees in about two years.
&#nl&#nl      "
  ["description"]=>
  string(198) "&#nl        
DEERFIELD, IL—Medical equipment maker Baxter International is expanding its Cleveland, MS, plant, with plans to add 50 to 100 new employees in about two years.
&#nl&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "99"
  ["rss_id"]=>
  string(2) "99"
  [14]=>
  string(82) "https://www.assemblymag.com/articles/94740-baxter-international-expanding-ms-plant"
  ["blog_url"]=>
  string(82) "https://www.assemblymag.com/articles/94740-baxter-international-expanding-ms-plant"
  [15]=>
  string(19) "2019-02-04 13:00:00"
  ["add_date"]=>
  string(19) "2019-02-04 13:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:22"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Baxter International Expanding MS Plant

&#nl

DEERFIELD, IL—Medical equipment maker Baxter International is expanding its Cleveland, MS, plant, w

array(40) {
  [0]=>
  string(4) "1747"
  ["article_id"]=>
  string(4) "1747"
  [1]=>
  string(117) "Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Agonist"
  ["article_title"]=>
  string(117) "Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Agonist"
  [2]=>
  string(150) "NEW HAVEN, Conn., Feb. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing"
  ["short_description"]=>
  string(150) "NEW HAVEN, Conn., Feb. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing"
  [3]=>
  string(251) "NEW HAVEN, Conn., Feb. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that administration of intranasal..."
  ["description"]=>
  string(251) "NEW HAVEN, Conn., Feb. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that administration of intranasal..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/biohaven-achieves-targeted-therapeutic-exposures-bhv-3500-third-generation-small-molecule-cgrp-18068.html?utm_source=ddc&utm_medium=rss&utm_campaign=Biohaven+Achieves+Targeted+Therapeutic+Exposures+of+BHV-3500%2C+a+Third-Generation+Small+Molecule+CGRP+Receptor+A"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/biohaven-achieves-targeted-therapeutic-exposures-bhv-3500-third-generation-small-molecule-cgrp-18068.html?utm_source=ddc&utm_medium=rss&utm_campaign=Biohaven+Achieves+Targeted+Therapeutic+Exposures+of+BHV-3500%2C+a+Third-Generation+Small+Molecule+CGRP+Receptor+A"
  [15]=>
  string(19) "2019-02-04 12:02:51"
  ["add_date"]=>
  string(19) "2019-02-04 12:02:51"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Mol

NEW HAVEN, Conn., Feb. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnolog

array(40) {
  [0]=>
  string(4) "1748"
  ["article_id"]=>
  string(4) "1748"
  [1]=>
  string(140) "VLP Therapeutics Receives FDA Clearance of Investigational New Drug Application and Initiates First Clinical Trial of VLPM01 Malaria Vaccine"
  ["article_title"]=>
  string(140) "VLP Therapeutics Receives FDA Clearance of Investigational New Drug Application and Initiates First Clinical Trial of VLPM01 Malaria Vaccine"
  [2]=>
  string(150) "Gaithersburg, MD – February 4, 2019 --  VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an in"
  ["short_description"]=>
  string(150) "Gaithersburg, MD – February 4, 2019 --  VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an in"
  [3]=>
  string(252) "Gaithersburg, MD – February 4, 2019 --  VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company’s VLPM01 malaria..."
  ["description"]=>
  string(252) "Gaithersburg, MD – February 4, 2019 --  VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company’s VLPM01 malaria..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/vlp-therapeutics-receives-fda-clearance-investigational-new-application-initiates-first-clinical-18067.html?utm_source=ddc&utm_medium=rss&utm_campaign=VLP+Therapeutics+Receives+FDA+Clearance+of+Investigational+New+Drug+Application+and+Initiates+First+Clinical+Tr"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/vlp-therapeutics-receives-fda-clearance-investigational-new-application-initiates-first-clinical-18067.html?utm_source=ddc&utm_medium=rss&utm_campaign=VLP+Therapeutics+Receives+FDA+Clearance+of+Investigational+New+Drug+Application+and+Initiates+First+Clinical+Tr"
  [15]=>
  string(19) "2019-02-04 12:02:03"
  ["add_date"]=>
  string(19) "2019-02-04 12:02:03"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

VLP Therapeutics Receives FDA Clearance of Investigational New Drug Application and Initia

Gaithersburg, MD – February 4, 2019 --  VLP Therapeutics today announced that the U.S. Food and Drug Administ

array(40) {
  [0]=>
  string(4) "5306"
  ["article_id"]=>
  string(4) "5306"
  [1]=>
  string(48) "Clinical NGS Data Analysis Nordic Workshop 2019 "
  ["article_title"]=>
  string(48) "Clinical NGS Data Analysis Nordic Workshop 2019 "
  [2]=>
  string(150) "This year, our annual Clinical NGS Data Analysis Nordic Workshop, led by the Bioinformatics team of Odense University Hospital (OUH), will take place "
  ["short_description"]=>
  string(150) "This year, our annual Clinical NGS Data Analysis Nordic Workshop, led by the Bioinformatics team of Odense University Hospital (OUH), will take place "
  [3]=>
  string(500) "This year, our annual Clinical NGS Data Analysis Nordic Workshop, led by the Bioinformatics team of Odense University Hospital (OUH), will take place in Copenhagen. The workshop will aim to go over the steps from acquisition of sequencing data to the generation of the bam- and vcf- files that will be used in the subsequent filtering for variants. Variants will be evaluated using various databases and prediction tools to establish potential pathogenic variants. Workshop delegates will be given..."
  ["description"]=>
  string(500) "This year, our annual Clinical NGS Data Analysis Nordic Workshop, led by the Bioinformatics team of Odense University Hospital (OUH), will take place in Copenhagen. The workshop will aim to go over the steps from acquisition of sequencing data to the generation of the bam- and vcf- files that will be used in the subsequent filtering for variants. Variants will be evaluated using various databases and prediction tools to establish potential pathogenic variants. Workshop delegates will be given..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(79) "https://www.pharmiweb.com/event/clinical-ngs-data-analysis-nordic-workshop-2019"
  ["blog_url"]=>
  string(79) "https://www.pharmiweb.com/event/clinical-ngs-data-analysis-nordic-workshop-2019"
  [15]=>
  string(19) "2019-02-01 19:23:00"
  ["add_date"]=>
  string(19) "2019-02-01 19:23:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:28"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Clinical NGS Data Analysis Nordic Workshop 2019

This year, our annual Clinical NGS Data Analysis Nordic Workshop, led by the Bioinformatics team of Odense University Ho

array(40) {
  [0]=>
  string(4) "5302"
  ["article_id"]=>
  string(4) "5302"
  [1]=>
  string(39) "Genomic Medicine 2019 Nordic Conference"
  ["article_title"]=>
  string(39) "Genomic Medicine 2019 Nordic Conference"
  [2]=>
  string(150) "Genomic Medicine Nordic Conference is an annual event organized by Biotexcel and partners. This year, the Nordic conference will take place in Copenha"
  ["short_description"]=>
  string(150) "Genomic Medicine Nordic Conference is an annual event organized by Biotexcel and partners. This year, the Nordic conference will take place in Copenha"
  [3]=>
  string(500) "Genomic Medicine Nordic Conference is an annual event organized by Biotexcel and partners. This year, the Nordic conference will take place in Copenhagen and, as always, it will focus on high throughput genomic technologies with a special focus on Next Generation Sequencing in the research and clinical analysis of human disease. As our contingent of loyal and returning delegates will be aware, the scientific theme will cover advances in the following areas: Genomics, Next Generation Sequencin..."
  ["description"]=>
  string(500) "Genomic Medicine Nordic Conference is an annual event organized by Biotexcel and partners. This year, the Nordic conference will take place in Copenhagen and, as always, it will focus on high throughput genomic technologies with a special focus on Next Generation Sequencing in the research and clinical analysis of human disease. As our contingent of loyal and returning delegates will be aware, the scientific theme will cover advances in the following areas: Genomics, Next Generation Sequencin..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(71) "https://www.pharmiweb.com/event/genomic-medicine-2019-nordic-conference"
  ["blog_url"]=>
  string(71) "https://www.pharmiweb.com/event/genomic-medicine-2019-nordic-conference"
  [15]=>
  string(19) "2019-02-01 19:21:41"
  ["add_date"]=>
  string(19) "2019-02-01 19:21:41"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:28"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Genomic Medicine 2019 Nordic Conference

Genomic Medicine Nordic Conference is an annual event organized by Biotexcel and partners. This year, the Nordic confere

array(40) {
  [0]=>
  string(4) "4503"
  ["article_id"]=>
  string(4) "4503"
  [1]=>
  string(65) "3rd Annual Conference on Hypertension and Cardiovascular Diseases"
  ["article_title"]=>
  string(65) "3rd Annual Conference on Hypertension and Cardiovascular Diseases"
  [2]=>
  string(150) "Hypertension 2019 welcomes attendees, presenters, and exhibitors from all over the world to Las Vegas, USA. We are delighted to invite you all to atte"
  ["short_description"]=>
  string(150) "Hypertension 2019 welcomes attendees, presenters, and exhibitors from all over the world to Las Vegas, USA. We are delighted to invite you all to atte"
  [3]=>
  string(530) "Hypertension 2019 welcomes attendees, presenters, and exhibitors from all over the world to Las Vegas, USA. We are delighted to invite you all to attend and register for the “3rd Annual Conference on Hypertension and Cardiovascular Disease” which is going to be held during October 09-10, 2019 Madrid, Spain.&#nl&#nlTo know more about the conference: https://hypertension.cmesociety.com/&#nl&#nl                                             (or)&#nl&#nlMail us at hypertension@pulsusevents.org / hypertension@cardiol..."
  ["description"]=>
  string(530) "Hypertension 2019 welcomes attendees, presenters, and exhibitors from all over the world to Las Vegas, USA. We are delighted to invite you all to attend and register for the “3rd Annual Conference on Hypertension and Cardiovascular Disease” which is going to be held during October 09-10, 2019 Madrid, Spain.&#nl&#nlTo know more about the conference: https://hypertension.cmesociety.com/&#nl&#nl                                             (or)&#nl&#nlMail us at hypertension@pulsusevents.org / hypertension@cardiol..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(99) "https://www.pharmiweb.com/event/3rd-annual-conference-on-hypertension-and-cardiovascular-diseases-1"
  ["blog_url"]=>
  string(99) "https://www.pharmiweb.com/event/3rd-annual-conference-on-hypertension-and-cardiovascular-diseases-1"
  [15]=>
  string(19) "2019-02-01 14:26:25"
  ["add_date"]=>
  string(19) "2019-02-01 14:26:25"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

3rd Annual Conference on Hypertension and Cardiovascular Diseases

Hypertension 2019 welcomes attendees, presenters, and exhibitors from all over the world to Las Vegas, USA. We are delig

array(40) {
  [0]=>
  string(4) "1706"
  ["article_id"]=>
  string(4) "1706"
  [1]=>
  string(120) "FDA Approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of Advair Diskus"
  ["article_title"]=>
  string(120) "FDA Approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of Advair Diskus"
  [2]=>
  string(150) "HERTFORDSHIRE, England and PITTSBURGH, Jan. 31, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. Food and Drug Administration (F"
  ["short_description"]=>
  string(150) "HERTFORDSHIRE, England and PITTSBURGH, Jan. 31, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. Food and Drug Administration (F"
  [3]=>
  string(249) "HERTFORDSHIRE, England and PITTSBURGH, Jan. 31, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. Food and Drug Administration (FDA) approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the..."
  ["description"]=>
  string(249) "HERTFORDSHIRE, England and PITTSBURGH, Jan. 31, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. Food and Drug Administration (FDA) approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-wixela-inhub-fluticasone-propionate-salmeterol-inhalation-powder-usp-first-advair-4913.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Wixela+Inhub+%28fluticasone+propionate+and+salmeterol+inhalation+powder%2C+USP%29%2C+First+Generic+of+Advair"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-wixela-inhub-fluticasone-propionate-salmeterol-inhalation-powder-usp-first-advair-4913.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Wixela+Inhub+%28fluticasone+propionate+and+salmeterol+inhalation+powder%2C+USP%29%2C+First+Generic+of+Advair"
  [15]=>
  string(19) "2019-02-01 04:01:28"
  ["add_date"]=>
  string(19) "2019-02-01 04:01:28"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP),

HERTFORDSHIRE, England and PITTSBURGH, Jan. 31, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. F

array(40) {
  [0]=>
  string(4) "4575"
  ["article_id"]=>
  string(4) "4575"
  [1]=>
  string(57) "39th Annual Conference on Dental Practice and Oral Health"
  ["article_title"]=>
  string(57) "39th Annual Conference on Dental Practice and Oral Health"
  [2]=>
  string(150) "In regard to the mind-boggling achievement of past Dental Practice Conferences, Conference Series Ltd heartily invites you to the 39th Annual Conferen"
  ["short_description"]=>
  string(150) "In regard to the mind-boggling achievement of past Dental Practice Conferences, Conference Series Ltd heartily invites you to the 39th Annual Conferen"
  [3]=>
  string(504) "In regard to the mind-boggling achievement of past Dental Practice Conferences, Conference Series Ltd heartily invites you to the 39th Annual Conference on Dental Practice and Oral Health to be held from September 16-17, 2019, Kyoto, Japan. Dental Practice 2019 aims to gather leading dental practitioners, dental doctors, educational scientists, researchers and research students to exchange & share their experiences, and research results about all aspects of Dental Practices. We invite all..."
  ["description"]=>
  string(504) "In regard to the mind-boggling achievement of past Dental Practice Conferences, Conference Series Ltd heartily invites you to the 39th Annual Conference on Dental Practice and Oral Health to be held from September 16-17, 2019, Kyoto, Japan. Dental Practice 2019 aims to gather leading dental practitioners, dental doctors, educational scientists, researchers and research students to exchange & share their experiences, and research results about all aspects of Dental Practices. We invite all..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(89) "https://www.pharmiweb.com/event/39th-annual-conference-on-dental-practice-and-oral-health"
  ["blog_url"]=>
  string(89) "https://www.pharmiweb.com/event/39th-annual-conference-on-dental-practice-and-oral-health"
  [15]=>
  string(19) "2019-01-31 18:48:51"
  ["add_date"]=>
  string(19) "2019-01-31 18:48:51"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:22"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

39th Annual Conference on Dental Practice and Oral Health

In regard to the mind-boggling achievement of past Dental Practice Conferences, Conference Series Ltd heartily invites y

array(40) {
  [0]=>
  string(4) "1714"
  ["article_id"]=>
  string(4) "1714"
  [1]=>
  string(96) "Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)"
  ["article_title"]=>
  string(96) "Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)"
  [2]=>
  string(150) "MARLBOROUGH, Mass.--(BUSINESS WIRE) January 30, 2019 --Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administra"
  ["short_description"]=>
  string(150) "MARLBOROUGH, Mass.--(BUSINESS WIRE) January 30, 2019 --Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administra"
  [3]=>
  string(242) "MARLBOROUGH, Mass.--(BUSINESS WIRE) January 30, 2019 --Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for..."
  ["description"]=>
  string(242) "MARLBOROUGH, Mass.--(BUSINESS WIRE) January 30, 2019 --Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(192) "https://www.drugs.com/nda/apl_130277_190130.html?utm_source=ddc&utm_medium=rss&utm_campaign=Sunovion+Receives+Complete+Response+Letter+from+FDA+for+Apomorphine+Sublingual+Film+%28APL-130277%29"
  ["blog_url"]=>
  string(192) "https://www.drugs.com/nda/apl_130277_190130.html?utm_source=ddc&utm_medium=rss&utm_campaign=Sunovion+Receives+Complete+Response+Letter+from+FDA+for+Apomorphine+Sublingual+Film+%28APL-130277%29"
  [15]=>
  string(19) "2019-01-31 05:01:29"
  ["add_date"]=>
  string(19) "2019-01-31 05:01:29"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-1

MARLBOROUGH, Mass.--(BUSINESS WIRE) January 30, 2019 --Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the

array(40) {
  [0]=>
  string(4) "1749"
  ["article_id"]=>
  string(4) "1749"
  [1]=>
  string(222) "Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children, and Adolescents"
  ["article_title"]=>
  string(222) "Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children, and Adolescents"
  [2]=>
  string(150) "KENILWORTH, N.J.--(BUSINESS WIRE) January 30, 2019 --Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that V11"
  ["short_description"]=>
  string(150) "KENILWORTH, N.J.--(BUSINESS WIRE) January 30, 2019 --Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that V11"
  [3]=>
  string(246) "KENILWORTH, N.J.--(BUSINESS WIRE) January 30, 2019 --Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, has received..."
  ["description"]=>
  string(246) "KENILWORTH, N.J.--(BUSINESS WIRE) January 30, 2019 --Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, has received..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/merck-receives-breakthrough-therapy-designation-fda-v114-s-investigational-15-valent-conjugate-18066.html?utm_source=ddc&utm_medium=rss&utm_campaign=Merck+Receives+Breakthrough+Therapy+Designation+from+FDA+for+V114%2C+the+Company%E2%80%99s+Investigational+15-Val"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/merck-receives-breakthrough-therapy-designation-fda-v114-s-investigational-15-valent-conjugate-18066.html?utm_source=ddc&utm_medium=rss&utm_campaign=Merck+Receives+Breakthrough+Therapy+Designation+from+FDA+for+V114%2C+the+Company%E2%80%99s+Investigational+15-Val"
  [15]=>
  string(19) "2019-01-30 11:02:31"
  ["add_date"]=>
  string(19) "2019-01-30 11:02:31"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s In

KENILWORTH, N.J.--(BUSINESS WIRE) January 30, 2019 --Merck (NYSE: MRK), known as MSD outside of the United States and Ca

array(40) {
  [0]=>
  string(4) "1750"
  ["article_id"]=>
  string(4) "1750"
  [1]=>
  string(214) "Scynexis Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies"
  ["article_title"]=>
  string(214) "Scynexis Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies"
  [2]=>
  string(150) "JERSEY CITY, N.J., Jan. 30, 2019 /PRNewswire/ -- Scynexis, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-"
  ["short_description"]=>
  string(150) "JERSEY CITY, N.J., Jan. 30, 2019 /PRNewswire/ -- Scynexis, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-"
  [3]=>
  string(248) "JERSEY CITY, N.J., Jan. 30, 2019 /PRNewswire/ -- Scynexis, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from the first..."
  ["description"]=>
  string(248) "JERSEY CITY, N.J., Jan. 30, 2019 /PRNewswire/ -- Scynexis, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive results from the first..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/scynexis-announces-positive-interim-results-phase-3-open-label-furi-study-showing-oral-18076.html?utm_source=ddc&utm_medium=rss&utm_campaign=Scynexis+Announces+Positive+Interim+Results+from+Phase+3+Open-Label+FURI+Study%2C+Showing+Oral+Ibrexafungerp%27s+Ability+"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/scynexis-announces-positive-interim-results-phase-3-open-label-furi-study-showing-oral-18076.html?utm_source=ddc&utm_medium=rss&utm_campaign=Scynexis+Announces+Positive+Interim+Results+from+Phase+3+Open-Label+FURI+Study%2C+Showing+Oral+Ibrexafungerp%27s+Ability+"
  [15]=>
  string(19) "2019-01-30 08:02:34"
  ["add_date"]=>
  string(19) "2019-01-30 08:02:34"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Scynexis Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Or

JERSEY CITY, N.J., Jan. 30, 2019 /PRNewswire/ -- Scynexis, Inc. (NASDAQ: SCYX), a biotechnology company delivering innov

array(40) {
  [0]=>
  string(4) "4501"
  ["article_id"]=>
  string(4) "4501"
  [1]=>
  string(24) "Liquid Biopsies Congress"
  ["article_title"]=>
  string(24) "Liquid Biopsies Congress"
  [2]=>
  string(150) "Liquid Biopsies can provide additional patient data less invasively than standard tissue biopsies.  The integration of liquid biopsies into clinical p"
  ["short_description"]=>
  string(150) "Liquid Biopsies can provide additional patient data less invasively than standard tissue biopsies.  The integration of liquid biopsies into clinical p"
  [3]=>
  string(512) "Liquid Biopsies can provide additional patient data less invasively than standard tissue biopsies.  The integration of liquid biopsies into clinical practice will enable a greater understanding of the patient through faster disease detection, earlier diagnosis, enhanced disease monitoring and treatment response and therefore delivering enhanced personalized healthcare.&#nl&#nl &#nl&#nlThis conference offers the biopharmaceutical industry the opportunity to examine the latest developments in the field wit..."
  ["description"]=>
  string(512) "Liquid Biopsies can provide additional patient data less invasively than standard tissue biopsies.  The integration of liquid biopsies into clinical practice will enable a greater understanding of the patient through faster disease detection, earlier diagnosis, enhanced disease monitoring and treatment response and therefore delivering enhanced personalized healthcare.&#nl&#nl &#nl&#nlThis conference offers the biopharmaceutical industry the opportunity to examine the latest developments in the field wit..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(56) "https://www.pharmiweb.com/event/liquid-biopsies-congress"
  ["blog_url"]=>
  string(56) "https://www.pharmiweb.com/event/liquid-biopsies-congress"
  [15]=>
  string(19) "2019-01-29 20:46:31"
  ["add_date"]=>
  string(19) "2019-01-29 20:46:31"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Liquid Biopsies Congress

Liquid Biopsies can provide additional patient data less invasively than standard tissue biopsies. The integration of l